UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.158

Sortiert nach

Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia

Saudi medical journal, 2024-07, Vol.45 (7), p.675-684

2024

Volltextzugriff (PDF)

Autoimmune diseases and their prevalence in Saudi Arabian patients with type 1 diabetes mellitus

Saudi medical journal, 2023-08, Vol.44 (8), p.751-760

2023

Volltextzugriff (PDF)

Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T‐cell lymphoma: a retrospective single‐centre case series

British journal of dermatology (1951), 2022-01, Vol.186 (1), p.153-166

2022

Volltextzugriff (PDF)

Design and Torsional Rigidity Analysis on Frame of Formula Garuda 17 Based on Student Formula Japan 2017 Rules

Journal of physics. Conference series, 2020-12, Vol.1700 (1), p.12060

2020

Volltextzugriff (PDF)

Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis

Hematological oncology, 2023-06, Vol.41 (S2), p.568-569

2023

Volltextzugriff (PDF)

Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology

Hematological oncology, 2023-06, Vol.41 (S2), p.499-500

2023

Volltextzugriff (PDF)

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

Leukemia, 2011-10, Vol.25 (10), p.1543-1547

2011

Volltextzugriff (PDF)

PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILE

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas

Bone marrow transplantation (Basingstoke), 2012-01, Vol.47 (1), p.65-72

2012

Volltextzugriff (PDF)

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.507-508

2019

Volltextzugriff (PDF)

PHASE 1/2 TRIAL OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) +/‐ LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES

Hematological oncology, 2019-06, Vol.37 (S2), p.519-520

2019

Volltextzugriff (PDF)

PET‐ADAPTED NIVOLUMAB +/‐ ICE AS INITIAL SALVAGE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.293-293

2019

Volltextzugriff (PDF)

Prostate cancer: some interesting facts

International journal of clinical practice (Esher), 2011-04, Vol.65 (4), p.514-515

2011

Volltextzugriff (PDF)

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS

Hematological oncology, 2019-06, Vol.37 (S2), p.280-281

2019

Volltextzugriff (PDF)

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

HemaSphere, 2022-06, Vol.6 (Suppl), p.1058-1059

2022

Volltextzugriff (PDF)

S262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES

HemaSphere, 2022-06, Vol.6, p.163-164

2022

Volltextzugriff (PDF)

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

Cancer chemotherapy and pharmacology, 2013-07, Vol.72 (1), p.241-249

2013

Volltextzugriff (PDF)

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM

Hematological oncology, 2017-06, Vol.35 (S2), p.411-412

2017

Volltextzugriff (PDF)

355 Significant disparities in prognosis and survival in Black cutaneous lymphoma patients emphasize the need for more focused study and care

Journal of investigative dermatology, 2021-05, Vol.141 (5), p.S62

2021

Volltextzugriff (PDF)

ERSN-OpenMC-Py: A python-based open-source software for OpenMC Monte Carlo code

Computer physics communications, 2024-06, Vol.299, p.109121, Article 109121

2024

Volltextzugriff (PDF)

453 Mogamulizumab associated rash (MAR) frequently mimics CTCL recurrence: A case series

Journal of investigative dermatology, 2021-05, Vol.141 (5), p.S78

2021

Volltextzugriff (PDF)

Dual blocking of CD47 and PD-L1 increases innate and adaptive immune responses in CTCL

European journal of cancer (1990), 2022-09, Vol.173, p.S2-S3

2022

Volltextzugriff (PDF)

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD

Bone marrow transplantation (Basingstoke), 2010-01, Vol.45 (1), p.205-207

2010

Volltextzugriff (PDF)

558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies

Annals of oncology, 2021-09, Vol.32, p.S615-S616

2021

Volltextzugriff (PDF)

1 – 25 von 1.158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(971)
Mit Volltextzugriff
(987)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(544)
Ingenta
(467)
MEDLINE
(407)
Ovid SocietyJournals and Single Titles
(298)
Single Journals
(272)
Elsevier ScienceDirect Journals
(233)
IngentaConnect Journals
(227)
Wiley-Blackwell Journals
(129)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(122)
Wiley Online Library Full Collection 2018
(81)
IEL
(68)
SpringerLink
(64)
Ebook Central Perpetual and DDA
(58)
eBooks on EBSCOhost
(55)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(43)
American Institute of Physics
(41)
Nature Journals
(38)
Oxford Journals
(27)
Access via Taylor & Francis
(27)
Springer Book Series
(26)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia

Autoimmune diseases and their prevalence in Saudi Arabian patients with type 1 diabetes mellitus

Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T‐cell lymphoma: a retrospective single‐centre case series

Design and Torsional Rigidity Analysis on Frame of Formula Garuda 17 Based on Student Formula Japan 2017 Rules

Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis

Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

PHASE 1 RESULTS OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) & LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA AND CORRELATION WITH GENE EXPRESSION PROFILE

Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL)

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA

PHASE 1/2 TRIAL OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) +/‐ LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES

PET‐ADAPTED NIVOLUMAB +/‐ ICE AS INITIAL SALVAGE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA

Prostate cancer: some interesting facts

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL LYMPHOMA: PHASE II RESULTS

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

S262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II‐IV PERIPHERAL T‐CELL NON‐HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T‐CELL CONSORTIUM

355 Significant disparities in prognosis and survival in Black cutaneous lymphoma patients emphasize the need for more focused study and care

ERSN-OpenMC-Py: A python-based open-source software for OpenMC Monte Carlo code

453 Mogamulizumab associated rash (MAR) frequently mimics CTCL recurrence: A case series

Dual blocking of CD47 and PD-L1 increases innate and adaptive immune responses in CTCL

Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD

558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies

Suchergebnisse filtern